Newsletter July 2025
Panel Screening Opportunity in TNBC Models
Dear Colleagues,
we’re offering a unique opportunity to evaluate your compound across a panel of 14 well-characterized triple-negative breast cancer (TNBC) models. This joint screening initiative enables you to benefit from shared controls, streamlined workflows, and competitive pricing — all while generating robust, translatable efficacy data. Optional add-on services such as IHC, PK/PD, and histology are also available to deepen your insights. EPO’s expertise in TNBC modeling and drug evaluation was recently featured in an oral presentation at AACR 2025 [Abstract] highlighting our leadership in translational oncology research.